Introduction: The changes in serum prostate specific antigen (PSA) concentrations can be used as a prognostic factor in patients undergoing maximum androgen blockade for metastatic prostate cancer.

Material And Method: A total of 149 patients followed up in our department were classified into 4 groups on the basis of PSA changes: group 1; those with normalisation of PSA levels within the first 3 months, group 2; those with normalisation PSA between months 3 and 6, group 3; those with a decrease in PSA but not reaching normal range, group 4; those with no decrease. The gleason scores and the number of bone metastases were also compared between the groups.

Result: The time to progression was significantly delayed in group 1 (mean: 23.3 months) compared to those with group 2 (mean: 16.9 months) (P<0.02). The time to progression in group 3 (mean: 8.45 months) was significantly shorter compared to the first two groups (P<0.001). Also, in patients with gleason scores 5-7 (grades 2) and gleason scores over 7 (grade 3) and group 1, the time to progression (mean: 21.2 months) was significantly delayed compared to those with the same gleason scores but with group 2 (mean: 13.4 months) (P<0.001).

Conclusion: The decrease in PSA level is more important than gleason scores in determining the time to progression. Early normalisation of PSA delays the time to progression, and when combined with gleason scores, PSA is an important prognostic factor in predicting the success of the therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11255-006-0096-0DOI Listing

Publication Analysis

Top Keywords

prostate specific
8
specific antigen
8
patients undergoing
8
undergoing maximum
8
maximum androgen
8
androgen blockade
8
blockade metastatic
8
metastatic prostate
8
group normalisation
8
normalisation psa
8

Similar Publications

Gastrin-releasing peptide receptors (GRPRs) overexpressed in many cancers are known as promising biomarkers to target tumors such as prostate, breast, and lung cancers. As the early diagnosis of the cancers can serve for better treatment of the patients, [In]In-DOTA-Pip-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 ([In]In-RM2) was prepared using an in-house developed Sn/In generator. 0.

View Article and Find Full Text PDF

Aim: Posterior tibial nerve stimulation (PTNS) might stimulate the sacral nerves and lead to work pelvic floor muscles. We evaluated to effects of PTNS on continence results after extraperitoneal laparoscopic radical prostatectomy (eLRP) with three trocars during early post operative period.

Methods: Prospectively recorded data of eLRP with three trocars was retrospectively reviewed for continence results between January 2017 and April 2024.

View Article and Find Full Text PDF

An optical biosensor is a specialized analytical device that utilizes the principles of optics and light in bimolecular processes. Localized surface plasmon resonance (LSPR) is a phenomenon in the realm of nanophotonics that occurs when metallic nanoparticles (NPs) or nanostructures interact with incident light. Conversely, surface-enhanced Raman spectroscopy (SERS) is an influential analytical technique based on Raman scattering, wherein it amplifies the Raman signals of molecules when they are situated near specific and specially designed nanostructures.

View Article and Find Full Text PDF

Aim/Objective The aim of this study was to investigate if diffuse, bilateral PI-RADS (Prostate Imaging Reporting and Data System) 3 changes, reported on MRI Prostate, harbour clinically significant prostate cancer (csPCa) within them. Methods Data from 108 men with diffuse, bilateral PI-RADS 3 changes on MRI of the prostate who underwent systematic prostate biopsy between January 2000 and November 2023 were analyzed. Histology results were classified as benign or malignant, and clinically significant prostate cancer (csPCa) was defined according to the European Association of Urology (EAU) guidelines as ISUP GG (International Society for Urological Pathology Grade Group) 2 or higher.

View Article and Find Full Text PDF

Background: The study aimed to overview radiopharmaceuticals used for the nuclear medicine (NM) imaging of prostate cancer (Pca) since the first mentions in the literature up to recent reports, with the special focus on positron emission tomography-computed tomography (PET-CT) radiotracers.

Materials And Methods: We found over 3500 articles discussing the role of PET-CT in Pca patients' management published within 1990-2023. We summarized the past and present interests of the Authors when the Pca diagnostic imaging and the use of radiotracers in Pca diagnosis are considered.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!